Abstract: Gastric cancer is diagnosed in nearly one million new patients each year and it remains the second leading cause of cancer-related deaths worldwide. Although gastric cancer represents a heterogeneous group of diseases, chronic inflammation has been shown to play a role in tumorigenesis. Cancer development is a multistep process characterized by genetic and epigenetic alterations during tumour initiation and progression. The stromal microenvironment is important in maintaining normal tissue homeostasis or promoting tumour development. A plethora of immune cells (i.e., lymphocytes, macrophages, mast cells, monocytes, myeloid-derived suppressor cells, Treg cells, dendritic cells, neutrophils, eosinophils, natural killer (NK) and natural killer T (NKT) cells) are components of gastric cancer microenvironment. Mast cell density is increased in gastric cancer and there is a correlation with angiogenesis, the number of metastatic lymph nodes and the survival of these patients. Mast cells exert a protumorigenic role in gastric cancer through the release of angiogenic (VEGF-A, CXCL8, MMP-9) and lymphangiogenic factors (VEGF-C and VEGF-F). Gastric mast cells express the programmed death ligands (PD-L1 and PD-L2) which are relevant as immune checkpoints in cancer. Several clinical undergoing trials targeting immune checkpoints could be an innovative therapeutic strategy in gastric cancer. Elucidation of the role of subsets of mast cells in different human gastric cancers will demand studies of increasing complexity beyond those assessing merely mast cell density and microlocalization.

Keywords: angiogenesis; cancer; gastric cancer; immune cells; inflammation; lymphangiogenesis; mast cells
1. Introduction

Gastric cancer is the fourth-most-common cancer globally and the second-leading cause of cancer deaths [1–3]. It accounts for nearly one million cases annually, with East Asia accounting for more than half of those cases [1,4]. In addition to incidence, the clinicopathologic characteristics of gastric cancer also differ among regions, especially Asia and the West [4,5]. Compelling evidence indicates that gastric cancer is a heterogeneous disease [6–9] on the basis of anatomic site [10], histopathology [11], gene expression [12–16], gene amplification [13,17], DNA methylation [13,18–20], relevant genetic aberrations [13,17,21–24] and oncogenic pathways [13,25,26].

Cancer development is a multistep process characterized by genomic instability, gene expression dysregulation and epigenetic abnormality that drive tumour progression [27]. Gene mutations and mutant cells are constantly generated but the immunosurveillance system detects and eliminates these cells [28]. However, immune-resistant cells evolve sophisticated strategies to evade the immune system and go on to generate tumours. Angiogenesis, the formation of new blood vessels, is essential for tumour growth, whereas lymphangiogenesis, the development of new lymphatic vessels, is important in the formation of metastases [29,30].

The stromal microenvironment plays a major role in maintaining normal tissue homoeostasis or promoting tumour growth. Mounting evidence indicates that normal tissue microenvironment is a barrier to tumorigenesis, whereas incorrect proinflammatory signals (e.g., cytokines, chemokines, reactive oxygen species, low pH, hypoxia, adenosine, etc.) destabilize tissue homeostasis and promote tumorigenesis [31]. Prolonged and uncontrolled low-grade inflammation or smouldering inflammation is a hallmark of cancer and several immune cells (macrophages, mast cells, lymphocytes, neutrophils, NK and NKT cells, etc.) are stromal components of the inflammatory microenvironment that modulates the development of experimental and human tumours [32–35].

Mast cells are immune cells present in all classes of vertebrates [36] which were identified in human tumour and named by Paul Ehrlich [37]. These cells have a widespread distribution in close proximity to epithelia, fibroblasts, blood and lymphatic vessels and nerves [38]. Human mast cells form a highly heterogeneous population of cells with different morphology, mediators and surface receptors [39]. These cells derive from CD34+, CD117+ (KIT) pluripotent hematopoietic stem cells in the bone marrow [40]. Mast cell progenitors enter the circulation and complete their maturation in tissues. These cells are involved in several physiological and inflammatory processes, including organ development [41], skin barrier homeostasis [42], angiogenesis [43], lymphangiogenesis [44], wound healing [45], heart function [46,47], coagulation [48] and tumorigenesis [35,49–55].

Mast cells have the capacity to rapidly perceive metabolic and immunologic insults and initiate different biochemical programs of homeostasis or inflammation. These cells are activated not only by IgE [56], specific antigens [57] and superantigens [58,59], the mechanisms which account for their functions in allergic diseases but also by a plethora of immunologic and non-immunologic stimuli [60–63].

Mast cell activation leads to the release of a large repertoire of biologically active mediators that have potential positive or negative effects on various targets [30,64,65]. Mast cell mediators have been canonically associated with a detrimental role in allergic diseases [38,39,57,66]. Given their presence in nearly all tissues and the plethora of proinflammatory and immunoregulatory mediators they produce and their capacity to interact closely with several immune and non-immune cells, mast cells are involved in several pathophysiological processes [67].

2. Mast Cells and Tumour Biology

Mast cells in human tumour were initially described by Paul Ehrlich and extended by Eugen Westphal [68]. Tumour-associated mast cells (TAMCs) are a component of the microenvironment of nearly all solid [49,69–82] and haematologic human tumours [83–93]. TAMCs may exert pro- or anti-tumorigenic roles depending on but not limited to, the tumour model, the stage and the type of tumour and their localization within the tumour (i.e., intra-tumoral vs peri-tumoral) [35,94]. In a few
cases, they appear to be inert bystanders [95–98]. Recent evidence indicates that mast cells [99,100], like macrophages [101–103] and neutrophils [104–106] are heterogeneous.

Mast cells are recruited into tumour microenvironment (TME) by several tumour cell-derived chemotactic factors. For example, stem cell factor (SCF) acts on the mast cell KIT receptor [62,107], vascular endothelial growth factors (VEGFs) act on VEGFR1 and VEGFR2 [44,79], angiopoietin 1 (ANGPT1) acts on TIE2 receptor [108] and CXCL8 acts on CXCR1 and CXCR2 [109]. Several chemokines (CCL2, CCL5, CXCL1, CXCL10 and CXCL12) produced by tumour and stromal cells activate their specific mast cell receptors (CCR2, CCR3, CXCR2, CXCR3 and CXCR4), which are important for TAM localization in TME [49,79,110–116].

Histamine, a major proinflammatory mediator released by activated mast cells, exerts a paracrine chemotactic effect through the engagement of histamine H4 receptor on mast cells [117]. PGE2, produced by several tumours, is chemotactic for mast cells through the activation of EP3 receptor [118]. Finally, osteopontin, which is upregulated in human cancer [49], affects mast cell migration [119].

Within the tumour microenvironment, TAMCs are exposed to and activated by several factors. Adenosine, produced by tumour cells and mast cells [120], is markedly increased in the TME [121,122] and potentiates the production of angiogenic factors from human mast cells and macrophages [109,123,124]. Hypoxia, a prominent feature of TME [121], activates human mast cells to release IL-6 [125] and VEGF-A [126]. Cyclooxygenase 2 (COX-2), overexpressed in tumours, [121] produces PGE2 which fosters angiogenic and lymphangiogenic factors from human mast cells [44]. Several chemokines (i.e., CXCL1, CXCL10, CXCL12) activate mast cells and enhance mast cell secretion of CXCL8 [79,115] which promotes epithelial-to-mesenchymal transition of cancer cells [109,124]. Increased expression of immunoglobulin free light chains (FLCs) was found in various human cancers, activates mast cells [127,128] and promotes tumour growth in a murine B16-F10 melanoma model [61]. Gastric cancer-derived adrenomedullin induced mast cell degranulation [129].

TAMCs modulate recruitment and activation of other immune cells at tumour sites. For example, TAMCs mobilize myeloid-derived suppressor cells (MDSCs) that foster tumour growth owing through their immunosuppressive properties [130]. Moreover, mast cells enhance MDSCs functions in vitro and in vivo [131–134].

3. Mast Cells in Tumour Angiogenesis and Lymphangiogenesis

Angiogenesis and lymphangiogenesis occur vigorously during embryogenesis but are restricted during adulthood [135]. In adults, angiogenesis and lymphangiogenesis are limited to sites of wound healing [136] and inflammation [137]. Angiogenesis is a hallmark of cancer because its induction is indispensable to fuel tumour growth [138]. Several innate immune cells can drive angiogenesis during tumour growth, primarily through the production of angiogenic molecules within the TME [65]. Tumour lymphangiogenesis may occur both within the primary tumour and/or in the tumour periphery [139] and plays a central role in the formation of metastasis [139,140]. Angiogenesis and lymphangiogenesis are controlled by stimulatory and inhibitory signals [29,135,141]. VEGF-A is a potent agonist of vascular endothelial growth factor receptor 2 (VEGFR2) on blood endothelial cells (BECs) [142]. VEGF-C and VEGF-D are crucial for the survival, proliferation and migration of lymphatic endothelial cells (LECs) [143] through the engagement of VEGFR3 [144].

VEGF-A, VEGF-B, VEGF-C, VEGF-D and placenta growth factor (PIGF) bind to three endothelial receptors: VEGFR1, VEGFR2 and VEGFR3 [145]. VEGF-A induces the survival, proliferation, sprouting and migration of BECs, increases endothelial permeability [146,147] and promotes inflammation [44,148,149]. VEGF-A also modulates lymphangiogenesis by binding to VEGFR2/VEGFR3 heterodimer receptor [142] and indirectly by recruiting immune cells (e.g., macrophages, mast cells) that produce VEGF-C and VEGF-D [44,150]. PIGF and VEGF-B bind to VEGFR1 on BECs [151], some immune cells and pericytes [148,149,152]. Angiopoietins (ANGPT1 and ANGPT2) modulate angiogenesis and lymphangiogenesis [153] through the engagement of TIE1 and TIE2 receptors [154]. ANGPT1 expressed by pericytes fosters BEC survival, whereas ANGPT2,
secreted by BECs, acts autocrinally and paracrinally as TIE2 ligand [153]. Human lung mast cells express TIE1 and TIE2 and ANGPT1 induces migration of these cells by binding to TIE2 [108]. Certain chemokines also modulate angiogenesis and lymphangiogenesis [155,156].

Figure 1 shows that several immune cells produce a variety of angiogenic and lymphangiogenic factors [43,44,51,123,137,147,149,156,157]. Immunologic and non-immunologic stimuli induce the release of VEGF-A from human mast cells [44,158–160]. These cells express different isoforms of VEGF-A (121, 165, 189 and 206) and their activation induces the release of VEGF-A [44]. Mast cells also express two isoforms of VEGF-B (167 and 186) and VEGF-C and VEGF-D. VEGFs induce mast cell chemotaxis in vitro [44] and in vivo [79] by binding to both VEGFR1 and VEGFR2. These cells also promote tumour growth by increasing the angiogenic supply, degradation of the extracellular matrix (ECM) and immunosuppression [161].

Figure 1. Representation of the immune landscape of human gastric cancer. The immune network in gastric cancer is a complex and dynamic system characterized by multiple interactions between a wide spectrum of immune cells, their mediators and tumour cells. Tumour-associated macrophages (TAM), M2 macrophages, tumour-associated mast cells, basophils, monocytes, polymorphonuclear-myeloid-derived suppressor cells (PMN-MDSCs), monocyte-derived suppressor cells (M-MDSCs), Tregs, Th2 cells, tumour-associated neutrophils (TAN), immature DCs (iDCs), Th17 cells and their mediators play protumorigenic roles. M1 macrophages, cytotoxic CD8+ T cells, NK cells, Th1 cells, mature DCs (mDCs) and their mediators play an anti-tumorigenic role in gastric cancer. VEGF-A and CXCL8 produced by tumour cells can activate tumour angiogenesis. Mast cells and macrophages are major producers of lymphangiogenic factors (VEGF-C and VEGF-D). The anti-tumorigenic role of Th9 cells, type I NKT cells and γδ T cells (grey and dashed lines) have been demonstrated in several other human cancers or are under investigation in gastric cancer. There is increasing evidence that eosinophils play an anti-tumorigenic role in different cancers [162–164]. The protumorigenic role of circulating Tfh cells [165] and of type II NKT cells has been preliminarily shown in gastric cancer or in several other human tumours, respectively (grey and dashed lines).
4. Mast Cells in the Immune Contexture of Cancer

Several studies have contributed to the characterization of the immune microenvironment of human gastric cancer. Figure 1 schematically illustrates the immune landscape of human gastric cancer. Several immune cells (M2 macrophages, TAM, mast cells, basophils, monocytes, PMN-MDSC, M-MDSC, Treg cells, Th2 cells, TAN, immature DCs and Th17/Te17 cells), localized in human gastric cancer, release a wide spectrum of proinflammatory, angiogenic, lymphangiogenic and immunomodulatory mediators that play a protumorigenic role. Other immune cells (M1 macrophages, cytotoxic CD8+ T cells, NK cells, Th1 cells and mature DCs) and their mediators can play an anti-tumorigenic role in cancer. Eosinophils are component of the immune microenvironment that modulates tumour initiation and progression [162,166]. There are several bidirectional mast cell-eosinophil interactions in inflammatory disorders and cancer [167]. Increasing evidence indicates that eosinophils play an anti-tumorigenic role in different cancers [162–164]. The pro- (Tfh cells, type II NKT cells) or anti-tumorigenic role (γδ T cells, type I NKT cells and Th9 cells) of several immune cells have been demonstrated in other human cancers or are still under investigation in gastric cancer.

In the majority of tumours, such as thyroid [79,109], gastric [168–171], pancreas [78,172–176], bladder [177] and colorectal [178–181] cancers, hepatocellular carcinoma [182–184], Merkel cell carcinoma [75], Hodgkin’s [85,86,88] and non-Hodgkin’s lymphoma [87,89,92] and plasmacytoma [90,185], mast cells conferred poor prognosis. In breast cancer mast cells appear to play an antitumorigenic role [186–188]. These findings indicate that the contribution of mast cells to cancer is tumour dependent.

Low mast cell density in perilesional stroma of invasive melanomas predicts poor prognosis [82], whereas, mast cell count was not correlated with survival in superficially invasive melanomas. Mast cells were pro-tumorigenic in the initial stages of prostate cancer but became dispensable at later stages [80,189]. A recent study examining a total of 9393 prostatectomy samples found that mast cell density was associated with better prognosis (i.e., distant metastasis-free survival) [190]. Peritumoral, but not intratumoral mast cell density, conferred a survival advantage in stage I non-small-cell lung cancer (NSCLC) but not in stage II [191]. The contributory role of mast cells in cancer varies according to the stage of tumorigenesis.

In prostate cancer, increased intratumoral mast cell density was associated with favourable prognosis [84]. Intratumoral mast cells inhibited tumour growth, whereas peritumoral mast cells stimulated human prostate cancer [76]. In NSCLC, mast cell in tumour islets was associated with a good prognosis [192,193], whereas only in stage I NSCLC increased peritumoral mast cells were conferred a survival advantage [191]. In pancreatic carcinoma, mast cell density in the intratumoral border zone but not the peritumoral or the intratumoral zone, was associated with disease progression [194]. The role of mast cells in melanoma depends on both the microlocalization of these cells [82] and the subtypes of tumour [195]. Mast cell density at the periphery of the tumours correlated with disease progression in both cutaneous T- and B-cell lymphoma [89]. Collectively, these findings indicate that the contribution of mast cells in tumours varies according to their microlocalization.

In conclusion, the results of several studies indicate that the pro- or anti-tumorigenic role(s) of mast cells in different tumours is cancer specific, depends on the stage of tumorigenesis and on their microlocalization. It is possible that different subtypes of mast cells play a protective role whereas other types play a protumorigenic role. Single-cell mapping of peritumoral and intratumoral mast cells could help to elucidate the roles of different subsets of mast cells in the onset and progression of different tumours.

5. Mast Cells in the Immune Contexture of Human Gastric Cancer

Mast cells were first identified in small groups of Italian patients with gastric cancer more than 50 years ago [196,197]. Mast cell density was also found increased in Japanese patients with gastric cancer compared to macroscopically normal tissue [198]. Mast cells in gastric cancer were found to be chymase+ and it was suggested that patients with high number of mast cells had a poor prognosis [199]. Helicobacter pylori (H. pylori) is the etiologic agent of chronic gastritis and is recognized as a class 1
carcinogen [3]. Mast cells, eosinophils and basophils are increased in *H. pylori*-induced gastritis [200–202]. An increased density of mast cells was reported in patients with chronic gastritis [203]. Interestingly, elevated eosinophil density was found in the gastric cancer low-risk area, whereas in the high-risk area the eosinophil infiltrate was reduced. The authors speculated that eosinophils may promote or limit chronic inflammation and tumorigenesis depending on the surrounding immune environment.

Ribatti and collaborators highlighted the correlation between mast cells and angiogenesis in gastric cancer [204]. A correlation was also found between mast cell density and both Foxp3+ Treg cells and different stages of gastric cancer [205]. A correlation was also found between KIT+ mast cells and angiogenesis evaluated as microvascular density [169] and between tryptase+ mast cells and the number of metastatic lymph nodes in different stages of gastric cancer [168]. Mast cell tryptase is one of the proangiogenic factors stored and released by human mast cells [35,51,66,206]. Tryptase activates the protease-activated receptor-2 (PAR-2) on endothelial cells and a correlation was found between mast cell density and PAR-2 on endothelial cells in gastric cancer [207]. Based on the above findings it has been proposed that targeting tryptase could be a potential anti-angiogenic strategy in gastric cancer [208]. Ammendola and co-workers made an interesting observation looking at mast cells in bone metastases from gastric cancer patients [209]. They described the presence of mast cells near blood vessels in bone metastases from gastric cancer and found a correlation between mast cell density and microvascular density. The latter observation led to suggest that tryptase inhibitors or KIT tyrosine kinase inhibitors could represent a novel strategy to inhibit tumour-induced angiogenesis and osteoclastic bone resorption [210].

IL-17 is a pleiotropic cytokine [211] identified in several tumours including gastric cancer [212,213]. Although it has long been considered that the major source of IL-17 are CD4+ T lymphocytes (Th17 cells), this cytokine can be produced by several immune cells, including cytotoxic CD8+ T cells (Tc17), γδ T cells, NKT and NK cells, macrophages, granulocytes and mast cells [214–216]. It has been shown that activated mast cells are capable of expanding Th17 cells through the release of IL-1β [217]. In a study of gastric cancer patients, it was found that mast cells and to a lesser extent macrophages stained positively for IL-17 [218]. Furthermore, endothelial cells expressed IL-17 receptor (IL-17R) and intratumor mast cells IL-17+ were associated with worse overall survival. Recently, the prognostic value of IL-17 mRNA and IL-17A+ cells has been studied in two independent large cohorts of Chinese gastric cancer patients [171]. The overall survival was longer in the high intratumoral IL-17A+ cell group than in the low intratumoral IL-17A+ cell group. The authors also examined the immune contexture in different IL-17A mRNA expression status. High IL-17A mRNA expression was associated with high proportion of activated mast cells, NK cells and Tregs, while it was associated with low proportion of M2 macrophages and resting mast cells. Finally, it has been reported that activated mast cells release IL-17A which promoted the in vitro proliferation of gastric cancer cells [129].

The role of mast cells has also been started to be evaluated in metastatic lymph nodes of gastric cancer patients. Although mast cells are rarely found in normal lymph nodes, local mastocytosis was demonstrated in lymph node metastases from primary gastric cancer [219]. Figure 2A illustrates the localization of tryptase+ mast cells in primary gastric cancer. Interestingly, tryptase+ mast cells were also found in lymph node metastasis from primary gastric cancer (Figure 2B). The role of metastasis-associated mast cells is of great interest considering the contribution of these cells to lymphangiogenesis through the production of lymphangiogenic factors [44,220,221].
Figure 2. (A) Primary gastric cancer tissue immunostained with an anti-tryptase antibody demonstrates the presence of several mast cells in red (single arrow). Big arrow indicates a blood vessel with a red blood cell in its lumen (40 ×). (B) Metastatic lymph node from primary gastric cancer immunostained with an anti-tryptase antibody. Single arrows indicate red stained mast cells; the big arrow indicates a lymphocyte and the double arrow indicates a blood vessel (40 ×). Reprinted from Ammendola et al. (Int. J. Mol. Sci. 17: E1905, 2016). Bars: A and B = 100 µm.
Recently, the spatial distribution of mast cells and vessels in peritumoral and intratumoral gastric cancer has been started to be investigated. It was found that tryptase+ chymase+ mast cells were preferentially located near the gastric glands and blood vessels [222]. In two large groups of patients with gastric cancer, peritumoral (area ≥ 2 cm from the tumour margin) and intratumoral (tumour centre area) mast cells were identified [171]. This study also examined the immune contexture of gastric cancer. CD4+ and CD8+ T cells, B cells, DCs, M0, M1 and M2 macrophages, monocytes, eosinophils, neutrophils, Th1 cells, Tregs, NK cells and plasma cells, in addition to mast cells, were found in the tumour microenvironment of gastric cancer [171]. The presence of mast cells and macrophages in gastric tumour microenvironment has been correlated to microvascular density [223]. The microlocalization of intratumoral, marginal, peritumoral and non-tumour issues of mast cells has been examined in gastric cancer patients [129]. These patients showed a higher mast cell infiltration in intratumoral tissues than marginal, peritumoral and non-tumour tissues. Moreover, as the cancer progressed from stage I to IV, the intratumoral mast cells increased, suggesting a possible protumorigenic role for these cells. It has been reported that mast cells accumulate in gastric cancer through the engagement of the chemokine receptor CXCR4 by CXCL12 produced by tumour cells [170].

Mast cells are immune sentinels in the surrounding microenvironment and rapidly perceive biochemical and immunological insults [39,67] through the engagement of a constellation of surface receptors [66]. These cells also express co-receptors for T-cells such as CD40 ligand (CD40L), tumour necrosis factor superfamily member 4 (OX40L), inducible costimulator ligand (ICOS-L). T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3) and programmed death ligands (PD-L1 and PD-L2) [224–226]. The latter receptors are particularly relevant as immune checkpoint inhibitors (ICIs) [227,228]. Controversial results are reported about the impact of PD-L1 expression in gastric cancer [229,230]. Interestingly, intratumoral mast cells from gastric cancer constitutively expressed PD-L1 but not other molecules with immunosuppression potential such as CTLA-4 and ICOS [170]. TNF-α selectively induced the overexpression of PD-L1 on gastric mast cells. When mast cells from tumour and non-tumour tissues of gastric cancer patients were co-cultured with autologous peripheral blood CD3+ T cells, only tumour infiltrating mast cells inhibited T cell proliferation and IFN-γ production suggesting a specific immunosuppressive function. This hypothesis was extended in in vivo experiments using the NOD/SCID mice bearing SGC-7901-derived gastric cancer. In this model PD-L1 blocking antibody reduced gastric cancer progression. These important studies have identified a novel mechanism by which mast cells can promote tumorigenesis in gastric cancer and provide a rationale for the treatment of gastric cancer patients with immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 pathway.

6. Outstanding Questions and Conclusions

Gastric cancer is a heterogeneous disease [6–9] and several subtypes have been described anatomically [10], histologically [11] and genetically [12,14–16]. Several groups have identified tryptase+ and tryptase+ chymase+ mast cells in human gastric cancer patients in Europe [168,204,207,219,222,223] and in Asia [198,199,205,218]. Mast cell density in tumour microenvironment was associated with poor prognosis [129,168,170,198,199,218], tumour angiogenesis [169,198,199,204,219] and the formation of lymph node [168,219] and bone metastases [209]. These observations led to suggest that angiogenesis blockade could represent a promising target for the treatment of gastric cancer [207,210,231,232]. The results of several clinical trials indicate that anti-angiogenic agents improve overall survival, progression-free survival and disease control rate in gastric cancer [233]. Unfortunately, no studies thus far have identified a predictive biomarker to assist patient selection for benefit from anti-angiogenic agents. It would be interesting to verify whether mast cell density and/or activation in gastric tumours represent a biomarker of response to anti-angiogenic agents in these patients.

Mast cells are rarely found in normal lymph nodes. Figure 2B and elegant studies by Ammendola and collaborators have demonstrated that the density of mast cells is markedly increased in metastatic draining lymph nodes of gastric cancer patients [168,219]. This suggests that mast cells can migrate to
tumour draining lymph nodes (TDLNs) where they can act as non-professional antigen presenting cells [234,235]. The mast cell contribution to the evolving microenvironment of TDLNs remains poorly understood. High-dimensional analysis, particularly single-cell RNA-seq, will be necessary to better characterize mast cells in TDLNs.

Tumour cells evade host immune attack by expressing several immune checkpoints such as PD-1 and its ligands (PD-L1 and PD-L2) in TME. Monoclonal antibodies targeting the PD-1/PD-L1 pathway unleash anti-tumour immunity and have revolutionized the management of a wide spectrum of malignancies [236]. PD-L1 is overexpressed in up to 50% of gastric cancers [237,238] and a large number of clinical trials are evaluating the efficacy of mAbs anti-PD-1 (i.e., nivolumab, pembrolizumab) (Table S1) and anti-PD-L1 (i.e., atezolizumab, avelumab, durvalumab) (Table S2) as monotherapy or in combination with anti-CTLA-4 (i.e., ipilimumab) or targeted therapies in the management of advanced-stage gastric cancer. Human mast cells express PD-L1 and, to a lesser extent, PD-L2 [224–226]. An interesting task will be to investigate whether the expression of PD-L1 on mast cells is correlated with PD-L1+ cancer cells in the context of immunotherapy of gastric cancer.

As shown for tumour-associated macrophages (M1, M2, etc.) [101–103] and tumour-associated neutrophils (N1 and N2) [104–106], subpopulations of mast cells are recently begun to emerge [99,100] and could play different, even opposite effects in various types of tumours. Mast cells, like other immune cells, are endowed with phenotypic and functional plasticity depending on environmental factors [239] which may vary in composition in the different cancers [240,241]. The complex heterogeneity (spatial, temporal, intratumoral) of the TME adds a further layer of complexity. Simultaneous single-cell analysis of the immune contexture of TME of different subtypes of human gastric cancers characterized by genetic markers can greatly expand our knowledge of the role of mast cells in tumour initiation and progression.

All the above implies that clarification of the roles of subsets of mast cells in different human gastric cancers will demand studies of complexity beyond those assessing merely mast cell density, their microlocalization and the interactions with other immune cells. Therefore, many fundamental questions need to be addressed before understanding how mast cells play a protumorigenic role in gastric tumours.

**Supplementary Materials:** Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/9/2106/s1.

**Author Contributions:** All authors have contributed to the preparation of this manuscript and have critically revised and accepted the final version for publication.

**Funding:** This work was supported in part by grants from the Regione Campania CISI-Lab Project, the CRèME Project and the TIMING Project.

**Acknowledgments:** The authors apologize to the many researchers who have contributed importantly to this field and whose work has not been cited due to space and citation restrictions. The authors thank Gjada Criscuolo for critical reading of the manuscript, scientists from the CISI Laboratory not listed as authors for invaluable collaborations, medical graphic artist Fabrizio Fiorbianco for preparing the figures and the administrative staff (Roberto Bifulco and Anna Ferraro), without whom we could not function as an integrated team.

**Conflicts of Interest:** The authors have no relevant affiliation or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending or royalties.

**Abbreviations**

| Abbreviation | Description |
|--------------|-------------|
| ANGPT | angiopoietin |
| BEC | blood endothelial cell |
| CD40 | cluster of differentiation 40 protein |
| CD40L | cluster of differentiation 40 ligand |
| COX | cyclooxygenase |
| DC | dendritic cell |
| ECM | extracellular matrix |
| FLC | free light chain |
ICI immune checkpoint inhibitor
ICOS inducible costimulator
ICOS-L inducible costimulator ligand
IFN interferon
IL interleukin
KIT stem cell factor receptor
LEC lymphatic endothelial cell
mAb monoclonal antibody
MDCS myeloid-derived suppressor cell
MMP matrix metalloproteinase
NK natural killer cell
NKT natural killer T cell
NSCLC non-small-cell lung cancer
PAR protease-activated receptor
PD-1 programmed death-1
PD-L1 programmed death ligand 1
PD-L2 programmed death ligand 2
PGE prostaglandin E
PlGF placental growth factor
PMN polymorphonuclear leukocyte
SCF stem cell factor
SCID severe combined immunodeficiency
TAM tumour-associated macrophage
TAMC tumour-associated mast cell
TAN tumour-associated neutrophils
TDLN tumour draining lymph node
Tfh T follicular helper cells
TIE Tyrosine kinase with immunoglobulin-like and EGF-like domains
TIM-3 T cell immunoglobulin and mucin domain-containing protein 3
TME tumour microenvironment
TNF tumour necrosis factor
VEGF Vascular endothelial growth factor
VEGFR Vascular endothelial growth factor receptor

References
1. Jemal, A.; Bray, F.; Center, M.M.; Ferlay, J.; Ward, E.; Forman, D. Global cancer statistics. CA Cancer J. Clin. 2011, 61, 69–90. [CrossRef]
2. Lott, P.C.; Carvajal-Carmona, L.G. Resolving gastric cancer aetiology: An update in genetic predisposition. Lancet Gastroenterol Hepatol. 2018, 3, 874–883. [CrossRef]
3. Van Cutsem, E.; Sagaert, X.; Topal, B.; Haustermans, K.; Prenen, H. Gastric cancer. Lancet. 2016, 388, 2654–2664. [CrossRef]
4. Russo, A.E.; Strong, V.E. Gastric Cancer Etiology and Management in Asia and the West. Annu. Rev. Med. 2019, 70, 353–367. [CrossRef]
5. Shim, J.H.; Song, K.Y.; Jeon, H.M.; Park, C.H.; Jacks, L.M.; Gonen, M.; Shah, M.A.; Brennan, M.F.; Coit, D.G.; Strong, V.E. Is gastric cancer different in Korea and the United States? Impact of tumor location on prognosis. Ann. Surg. Oncol. 2014, 21, 2332–2339. [CrossRef]
6. Gullo, I.; Carneiro, F.; Oliveira, C.; Almeida, G.M. Heterogeneity in Gastric Cancer: From Pure Morphology to Molecular Classifications. Pathobiology 2018, 85, 50–63. [CrossRef]
7. Gao, J.P.; Xu, W.; Liu, W.T.; Yan, M.; Zhu, Z.G. Tumor heterogeneity of gastric cancer: From the perspective of tumor-initiating cell. World J. Gastroenterol. 2018, 24, 2567–2581. [CrossRef] [PubMed]
8. Chia, N.Y.; Tan, P. Molecular classification of gastric cancer. Ann. Oncol. 2016, 27, 763–769. [CrossRef] [PubMed]
9. Cislo, M.; Filip, A.A.; Arnold Offerhaus, G.J.; Cisel, B.; Rawicz-Pruszynski, K.; Skierucha, M.; Polkowski, W.P. Distinct molecular subtypes of gastric cancer: From Lauren to molecular pathology. *Oncotarget* **2018**, *9*, 19427–19442. [CrossRef] [PubMed]

10. Wang, G.; Hu, N.; Yang, H.H.; Wang, L.; Su, H.; Wang, C.; Clifford, R.; Dawsey, E.M.; Li, J.M.; Ding, T.; et al. Comparison of global gene expression of gastric cardia and noncardia cancers from a high-risk population in China. *PLoS ONE* **2013**, *8*, e63826. [CrossRef]

11. Shah, M.A.; Khanin, R.; Tang, L.; Janjigian, Y.Y.; Klimstra, D.S.; Gerdes, H.; Kelsen, D.P. Molecular classification of gastric cancer: A new paradigm. *Clin. Cancer Res.* **2011**, *17*, 2693–2701. [CrossRef]

12. Tay, S.T.; Leong, S.H.; Yu, K.; Aggarwal, A.; Tan, S.Y.; Lee, C.H.; Wong, K.; Visvanathan, J.; Lim, D.; Wong, W.K.; et al. A combined comparative genomic hybridization and expression microarray analysis of gastric cancer reveals novel molecular subtypes. *Cancer Res.* **2003**, *63*, 3309–3316.

13. The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. *Nature* **2014**, *513*, 202–209. [CrossRef]

14. Chen, X.; Leung, S.Y.; Yuen, S.T.; Chu, K.M.; Ji, J.; Li, R.; Chan, A.S.; Law, S.; Troyanskaya, O.G.; Wong, J.; et al. Variation in gene expression patterns in human gastric cancers. *Mol. Biol. Cell* **2003**, *14*, 3208–3215. [CrossRef] [PubMed]

15. Tan, I.B.; Ivanova, T.; Lim, K.H.; Ong, C.W.; Deng, N.; Lee, J.; Tan, S.H.; Wu, J.; Lee, M.H.; Ooi, C.H.; et al. Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. *Gastroenterology* **2011**, *141*, 476–485, 485.e1–485.e11. [CrossRef] [PubMed]

16. Cho, J.Y.; Lim, J.Y.; Cheong, J.H.; Park, Y.Y.; Yoon, S.L.; Kim, S.M.; Kim, S.B.; Kim, H.; Hong, S.W.; Park, Y.N.; et al. Gene expression signature-based prognostic risk score in gastric cancer. *Clin. Cancer Res.* **2011**, *17*, 1850–1857. [CrossRef] [PubMed]

17. Deng, N.; Goh, L.K.; Wang, H.; Das, K.; Tao, J.; Tan, I.B.; Zhang, S.; Lee, M.; Wu, J.; Lim, K.H.; et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. *Gut* **2012**, *61*, 673–684. [Gut] [PubMed]

18. An, C.; Choi, I.S.; Yao, J.C.; Worah, S.; Xie, K.; Mansfield, P.F.; Ajani, J.A.; Rashid, A.; Hamilton, S.R.; Wu, T.T. Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma. *Clin. Cancer Res.* **2005**, *11*, 656–663.

19. Liu, Z.; Zhang, J.; Gao, Y.; Pei, L.; Zhou, J.; Gu, L.; Zhang, L.; Zhu, B.; Hattori, N.; Ji, J.; et al. Large-scale characterization of DNA methylation changes in human gastric carcinomas with and without metastasis. *Clin. Cancer Res.* **2014**, *20*, 4598–4612. [CrossRef]

20. Zouridis, H.; Deng, N.; Ivanova, T.; Zhu, Y.; Wong, B.; Huang, D.; Wu, Y.H.; Wu, Y.; Tan, I.B.; Liem, N.; et al. Methylation subtypes and large-scale epigenetic alterations in gastric cancer. *Sci. Transl. Med.* **2012**, *4*, 156ra140. [PubMed]

21. Wang, K.; Yuen, S.T.; Xu, J.; Lee, S.P.; Yan, H.H.; Shi, S.T.; Siu, H.C.; Deng, S.; Chu, K.M.; Law, S.; et al. Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. *Nat. Genet.* **2014**, *46*, 573–582. [CrossRef]

22. Kakiuchi, M.; Nishizawa, T.; Ueda, H.; Gotoh, K.; Tanaka, A.; Hayashi, A.; Yamamoto, S.; Tatsuno, K.; Katoh, H.; Watanabe, Y.; et al. Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma. *Nat. Genet.* **2014**, *46*, 583–587. [CrossRef]

23. Liu, J.; McCleland, M.; Stawiski, E.W.; Gnad, F.; Mayba, O.; Haverty, P.M.; Durinck, S.; Chen, Y.J.; Klijn, C.; Junghunwala, S.; et al. Integrated exome and transcriptome sequencing reveals ZAK isoform usage in gastric cancer. *Nat. Commun.* **2014**, *5*, 3830. [CrossRef]

24. Wong, S.S.; Kim, K.M.; Ting, J.C.; Yu, K.; Fu, J.; Liu, S.; Cristescu, R.; Nebozhyn, M.; Gong, L.; Yue, Y.G.; et al. Genomic landscape and genetic heterogeneity in gastric adenocarcinoma revealed by whole-genome sequencing. *Nat. Commun.* **2014**, *5*, 5477. [CrossRef]

25. Ooi, C.H.; Ivanova, T.; Wu, J.; Lee, M.; Tan, I.B.; Tao, J.; Ward, L.; Koo, J.H.; Gopalakrishnan, V.; Zhu, Y.; et al. Oncogenic pathway combinations predict clinical prognosis in gastric cancer. *PLoS Genet.* **2009**, *5*, e1000676. [CrossRef]

26. Wu, Y.; Grabsch, H.; Ivanova, T.; Tan, I.B.; Murray, J.; Ooi, C.H.; Wright, A.I.; West, N.P.; Hutchins, G.G.; Wu, J.; et al. Comprehensive genomic meta-analysis identifies intra-tumoural stroma as a predictor of survival in patients with gastric cancer. *Gut* **2013**, *62*, 1100–1111. [CrossRef]
Galdiero, M.R.; Varricchi, G.; Marone, G. The immune network in thyroid cancer. *Oncoimmunology* 2016, 5, e116856. [CrossRef]

Varricchi, G.; Galdiero, M.R.; Loffredo, S.; Marone, G.; Iannone, R.; Granata, F. Are Mast Cells MASTers in Cancer? *Front. Immunol.* 2017, 8, 424. [CrossRef]

Oskeritzian, C.A. Mast cell plasticity and sphingosine-1-phosphate in immunity, inflammation and cancer. *Mol. Immunol.* 2015, 63, 104–112. [CrossRef]

Rigoni, A.; Colombo, M.P.; Pucillo, C. Mast cells, basophils and eosinophils: From allergy to cancer. *Semin. Immunol.* 2018, 35, 29–34. [CrossRef]

Jarido, V.; Kennedy, L.; Hargrove, L.; Demieville, J.; Thompson, J.; Stephenson, K.; Francis, H. The emerging role of mast cells in liver disease. *Am. J. Physiol. Gastrointest. Liver Physiol.* 2017, 313, G89–G101. [CrossRef]

Oldford, S.A.; Marshall, J.S. Mast cells as targets for immunotherapy of solid tumors. *Mol. Immunol.* 2015, 63, 113–124. [CrossRef]

Jimenez-Andrade, G.Y.; Ibarra-Sanchez, A.; Gonzalez, D.; Lamas, M.; Gonzalez-Espinosa, C. Immunoglobulin E induces VEGF production in mast cells and potentiates their pro-tumorigenic actions through a Fyn kinase-dependent mechanism. *J. Hematol. Oncol.* 2013, 6, 56. [CrossRef]

Galli, S.J.; Tsai, M. IgE and mast cells in allergic disease. *Nat. Med.* 2012, 18, 693–704. [CrossRef]

Genovese, A.; Borgia, G.; Bjorck, L.; Petraroli, A.; de Paulis, A.; Piazza, M.; Marone, G. Immunoglobulin superantigen protein L induces IL-4 and IL-13 secretion from human Fc epsilon RI+ cells through interaction with the kappa light chains of IgE. *J. Immunol.* 2003, 170, 1854–1861. [CrossRef]

Marone, G.; Rossi, F.W.; Detoraki, A.; Granata, F.; Genovese, A.; Spadaro, G. Role of superallergens in allergic disorders. *Chen. Immunol. Allergy. Severity. 2007, 93, 195–213.

Andreu, P.; Johansson, M.; Affara, N.I.; Pucci, F.; Tan, T.; Junankar, S.; Korets, L.; Lam, J.; Tawfik, D.; DeNardo, D.G.; et al. FcγR activation regulates inflammation-associated squamous carcinogenesis. *Cancer Cell.* 2010, 17, 121–134. [CrossRef]

Groot Kormelink, T.; Powe, D.G.; Kuijpers, S.A.; Abdoukelimu, A.; Fens, M.H.; Pieters, E.H.; Kassing van der Ven, W.W.; Habashy, H.O.; Ellis, I.O.; Blokhuis, B.R.; et al. Immunoglobulin free light chains are biomarkers of poor prognosis in basal-like breast cancer and are potential targets in tumor-associated inflammation. *Oncotarget* 2014, 5, 3159–3167. [CrossRef]

Huang, B.; Lei, Z.; Zhang, G.M.; Li, D.; Song, C.; Li, B.; Liu, Y.; Yuan, Y.; Unkeless, J.; Xiong, H.; et al. SCF-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor microenvironment. *Blood* 2008, 112, 1269–1279. [CrossRef]

Oldford, S.A.; Haidl, I.D.; Howatt, M.A.; Leiva, C.A.; Johnston, B.; Marshall, J.S. A critical role for mast cells and mast cell-derived IL-6 in TLR2-mediated inhibition of tumor growth. *J. Immunol.* 2010, 185, 7067–7076. [CrossRef]

Krystal-Whittemore, M.; Dileepan, K.N.; Wood, J.G. Mast Cell: A Multi-Functional Master Cell. *Front. Immunol.* 2015, 6, 620. [CrossRef]

Varricchi, G.; Loffredo, S.; Galdiero, M.R.; Marone, G.; Cristinziano, L.; Granata, F. Innate effector cells in angiogenesis and lymphangiogenesis. *Curr. Opin. Immunol.* 2018, 53, 152–160. [CrossRef]

Borriello, F.; Granata, F.; Varricchi, G.; Genovese, A.; Triggiani, M.; Marone, G. Immunopharmacological modulation of mast cells. *Curr. Opin. Pharmacol.* 2014, 17, 45–57. [CrossRef]

Varricchi, G.; Rossi, F.W.; Galdiero, M.R.; Granata, F.; Criscuolo, G.; Spadaro, G.; de Paulis, A.; Marone, G. Physiological roles of mast cells. *Int. Arch. Allergy Immunol.* 2019, in press. [CrossRef]

Westphal, E. Über Mastzellen. In *Farbenanalytische Untersuchungen*; Ehrlich, P., Ed.; Hirschwald: Berlin, Germany, 1891; pp. 17–41.

Dvorak, A.M.; Mihm, M.C., Jr.; Osage, J.E.; Dvorak, H.F. Melanoma. An ultrastructural study of the host inflammatory and vascular responses. *J. Investig. Dermatol.* 1980, 75, 388–393. [CrossRef]

Takahashi, K.; Mulliken, J.B.; Kozakewich, H.P.; Rogers, R.A.; Folkman, J.; Ezekowitz, R.A. Cellular markers that distinguish the phases of hemangioma during infancy and childhood. *J. Clin. Investig.* 1994, 93, 2357–2364. [CrossRef]

Toth-Jakatics, R.; Jimi, S.; Takebayashi, S.; Kawamoto, N. Cutaneous malignant melanoma: Correlation between neovascularization and peritumor accumulation of mast cells overexpressing vascular endothelial growth factor. *Hum. Pathol.* 2000, 31, 955–960.
72. Aoki, M.; Pawankar, R.; Niimi, Y.; Kawana, S. Mast cells in basal cell carcinoma express VEGF, IL-8 and RANTES. *Int. Arch. Allergy Immunol.* 2003, 130, 216–223. [CrossRef]

73. Ribatti, D.; Ennas, M.G.; Vacca, A.; Ferreli, F.; Nico, B.; Orru, S.; Sirigui, P. Tumor vascularity and tryptase-positive mast cells correlate with a poor prognosis in melanoma. *Eur. J. Clin. Investig.* 2003, 33, 420–425. [CrossRef]

74. Ribatti, D.; Vacca, A.; Ria, R.; Marzullo, A.; Nico, B.; Filotico, R.; Roncali, L.; Dammacco, F. Neovascularisation, expression of fibroblast growth-factor-2 and mast cells with tryptase activity increase simultaneously with pathological progression in human malignant melanoma. *Eur. J. Cancer* 2003, 39, 666–674. [CrossRef]

75. Beer, T.W.; Ng, L.B.; Murray, K. Mast cells have prognostic value in Merkel cell carcinoma. *Am. J. Dermatopathol.* 2008, 30, 27–30. [CrossRef]

76. Johansson, A.; Rudolfsson, S.; Hammarsten, P.; Halin, S.; Pietras, K.; Jones, J.; Stattin, P.; Egevad, L.; Granfors, T.; Wikstrom, P.; et al. Mast cells are novel independent prognostic markers in prostate cancer and represent a target for therapy. *Am. J. Pathol.* 2010, 177, 1031–1041. [CrossRef]

77. Ng, L.; Beer, T.W.; Murray, K. Vascular density has prognostic value in Merkel cell carcinoma. *Am. J. Dermatopathol.* 2008, 30, 442–445. [CrossRef]

78. Ma, Y.; Hwang, R.F.; Logsdon, C.D.; Ullrich, S.E. Dynamic mast cell-stromal cell interactions promote growth of pancreatic cancer. *Cancer Res.* 2013, 73, 3927–3937. [CrossRef]

79. Melillo, R.M.; Guarino, V.; Avilla, E.; Galdiero, M.R.; Liotti, F.; Prevete, N.; Rossi, F.W.; Basolo, F.; Ugolini, C.; de Paulis, A.; et al. Mast cells have a protumorigenic role in human thyroid cancer. *Oncogene* 2010, 29, 6203–6215. [CrossRef]

80. Pittoni, P.; Tripodo, C.; Picone, S.; Mauri, G.; Parenza, M.; Rigoni, A.; Sangaletti, S.; Colombo, M.P. Mast cell targeting hampers prostate adenocarcinoma development but promotes the occurrence of highly malignant neuroendocrine cancers. *Cancer Res.* 2011, 71, 5987–5997. [CrossRef]

81. Johnson, C.; Huynh, V.; Hargrove, L.; Kennedy, L.; Graf-Eaton, A.; Owens, J.; Trzeciakowski, J.P.; Pittoni, P.; Tripodo, C.; Piconese, S.; Mauri, G.; Parenza, M.; Rigoni, A.; Sangaletti, S.; Colombo, M.P. Mast cell density and pathological progression in human malignant melanoma. *Eur. J. Cancer* 2003, 39, 1836–1849. [CrossRef]

82. Siiskonen, H.; Poukka, M.; Bykachev, A.; Tyynela-Korhonen, K.; Sironen, R.; Pasonen-Seppanen, S.; Harvima, I.T. Low numbers of tryptase+ and chymase+ mast cells associated with reduced survival and advanced tumor stage in melanoma. *Melanoma Res.* 2015, 25, 479–485. [CrossRef]

83. Fleischmann, A.; Schloem, T.; Kollermann, J.; Sekulic, N.; Huland, H.; Mirlacher, M.; Sauter, G.; Simon, R.; Erbersdobler, A. Immunological microenvironment in prostate cancer: High mast cell densities are associated with favorable tumor characteristics and good prognosis. *Prostate* 2009, 69, 976–981. [CrossRef]

84. Andersen, M.D.; Kamper, P.; Nielsen, P.S.; Bendix, K.; Ribe-Hansen, R.; Steiniche, T.; Hamilton-Dutoit, S.; Clausen, M.; d’Amore, F. Tumour-associated mast cells in classical Hodgkin’s lymphoma: Correlation with histological subtype, other tumour-infiltrating inflammatory cell subsets and outcome. *Eur. J. Haematol.* 2016, 96, 252–259. [CrossRef]

85. Englund, A.; Molin, D.; Enblad, B.; Karlén, J.; Glimelius, I.; Ljungman, G.; Amini, R.M. The role of tumour-infiltrating eosinophils, mast cells and macrophages in Classical and Nodular Lymphocyte Predominant Hodgkin Lymphoma in children. *Eur. J. Haematol.* 2016, 97, 430–438. [CrossRef]

86. Franco, G.; Guarnotta, C.; Frossi, B.; Piccaluga, P.P.; Boveri, E.; Gulino, A.; Fuligni, F.; Rigoni, A.; Porcasi, R.; Buffa, S.; et al. Bone marrow stroma CD40 expression correlates with inflammatory mast cell infiltration and disease progression in splenic marginal zone lymphoma. *Blood* 2014, 123, 1836–1849. [CrossRef]

87. Rabenhorst, A.; Schlaak, M.; Heukamp, L.C.; Forster, A.; Theurich, S.; von Bergwelt-Baildon, M.; Buttner, R.; Kurschat, P.; Mauch, C.; Roers, A.; et al. Mast cells play a protumorigenic role in primary cutaneous lymphoma. *Blood* 2012, 120, 2042–2054. [CrossRef]
91. Taskinen, M.; Karjalainen-Lindsberg, M.L.; Leppa, S. Prognostic influence of tumor-infiltrating mast cells in patients with follicular lymphoma treated with rituximab and CHOP. *Blood* 2008, 111, 4664–4667. [CrossRef]
92. Tripodo, C.; Gri, G.; Piccaluga, P.P.; Fossi, B.; Guarinotta, C.; Piconese, S.; Franco, G.; Vetri, V.; Pucillo, C.E.; Florena, A.M.; et al. Mast cells and Th17 cells contribute to the lymphoma-associated pro-inflammatory microenvironment of angiioimmunoblastic T-cell lymphoma. *Am. J. Pathol.* 2010, 177, 792–802. [CrossRef]
93. Vyzoukaki, R.; Tsirakis, G.; Pappa, C.A.; Devetzoglou, M.; Tzardi, M.; Alexandrakis, M.G. The Impact of Mast Cell Density on the Progression of Bone Disease in Multiple Myeloma Patients. *Int. Arch. Allergy Immunol.* 2015, 168, 263–268. [CrossRef]
94. Marichal, T.; Tsai, M.; Galli, S.J. Mast cells: Potential positive and negative roles in tumor biology. *Cancer Immunol. Res.* 2013, 1, 269–279. [CrossRef]
95. Antsiferova, M.; Martin, C.; Huber, M.; Feyerabend, T.B.; Forster, A.; Hartmann, K.; Rodewald, H.R.; Hohl, D.; Werner, S. Mast cells are dispensable for normal and activin-promoted wound healing and skin carcinogenesis. *J. Immunol.* 2013, 191, 6147–6155. [CrossRef]
96. Xia, Q.; Wu, X.J.; Zhou, Q.; Jing, Z.; Hou, J.H.; Pan, Z.Z.; Zhang, X.S. No relationship between the distribution of mast cells and the survival of stage IIIB colon cancer patients. *J. Transl. Med.* 2011, 9, 88. [CrossRef]
97. Dundar, E.; Oner, U.; Peker, B.C.; Metintas, M.; Isiksoy, S.; Ak, G. The significance and relationship between mast cells and tumour angiogenesis in non-small cell lung carcinoma. *J. Int. Med. Res.* 2008, 36, 88–95. [CrossRef]
98. Tuna, B.; Yorukoglu, K.; Unlu, M.; Mungan, M.U.; Kirkali, Z. Association of mast cells with microvessel density in renal cell carcinomas. *Eur. Urol.* 2006, 50, 530–534. [CrossRef]
99. Gentek, R.; Ghigo, C.; Hoe, M.; Feyerabend, T.B.; Forster, A.; Hartmann, K.; Rodewald, H.R.; Hohl, D.; Werner, S. Mast cells are dispensable for normal and activin-promoted wound healing and skin carcinogenesis. *J. Immunol.* 2013, 191, 6147–6155. [CrossRef]
100. Li, Z.; Liu, S.; Xu, J.; Zhang, X.; Han, D.; Liu, J.; Xia, M.; Yi, L.; Shen, Q.; Xu, S.; et al. Adult Connective Tissue-Resident Mast Cells Originate from Late Erythro-Myeloid Progenitors. *Immunity* 2018, 49, 640–653.e5. [CrossRef]
101. Mantovani, A.; Marchesi, F.; Malesci, A.; Laghi, L.; Allavena, P. Tumour-associated macrophages as treatment targets in oncology. *Nat. Rev. Clin. Oncol.* 2017, 14, 399–416. [CrossRef]
102. Chevrier, S.; Levine, J.H.; Zanotelli, V.R.T.; Silina, K.; Schulz, D.; Bacac, M.; Ries, C.H.; Ailles, L.; Jewett, M.A.S.; Moch, H.; et al. An Immune Atlas of Clear Cell Renal Cell Carcinoma. *Cell* 2017, 169, 736–749.e18. [CrossRef]
103. Aran, D.; Looney, A.P.; Liu, L.; Wu, E.; Fong, V.; Hsu, A.; Chak, S.; Naikawadi, R.P.; Wolters, P.J.; Abate, A.R.; et al. Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. *Nat. Immunol.* 2019, 20, 163–172. [CrossRef]
104. Jaillon, S.; Galdiero, M.R.; Del Prete, D.; Cassatella, M.A.; Garlanda, C.; Mantovani, A. Neutrophils in innate and adaptive immunity. *Semin. Immunopathol.* 2013, 35, 377–394. [CrossRef]
105. Shaul, M.E.; Levy, L.; Sun, J.; Mishallain, I.; Singhal, S.; Kapoor, V.; Horng, W.; Fridlender, G.; Albelda, S.M.; Fridlender, Z.G. Tumor-associated neutrophils display a distinct N1 profile following TGFbeta modulation: A transcriptomics analysis of pro- vs. antitumor TANs. *Oncoimmunology* 2016, 5, e1232221. [CrossRef]
106. Visciano, C.; Liotti, F.; Prevete, N.; Cali, G.; Franco, R.; Collina, F.; de Paulis, A.; Marone, G.; Santoro, M.; Melillo, R.M. Mast cells induce epithelial-to-mesenchymal transition and stem cell features in human thyroid cancer cells through an IL-8-Akt-Slug pathway. *Oncogenes* 2015, 34, 5175–5186. [CrossRef]
107. Yamamoto, T.; Katayama, I.; Nishio, K. Expression of stem cell factor in basal cell carcinoma. *Br. J. Dermatol.* 1997, 137, 709–713. [CrossRef]
108. Preve, N.; Staiano, R.I.; Granata, F.; Detoraki, A.; Necchi, V.; Ricci, V.; Triggiani, M.; De Paulis, A.; Marone, G.; Genovese, A. Expression and function of Angiopoietins and their tie receptors in human basophils and mast cells. *J. Biol. Regul. Homeost. Agents* 2013, 27, 827–839.
109. Visciano, C.; Liotti, F.; Prevete, N.; Cali, G.; Franco, R.; Collina, F.; de Paulis, A.; Marone, G.; Santoro, M.; Melillo, R.M. Mast cells induce epithelial-to-mesenchymal transition and stem cell features in human thyroid cancer cells through an IL-8-Akt-Slug pathway. *Oncogenes* 2015, 34, 5175–5186. [CrossRef]
110. Fischer, M.; Juremalm, M.; Olsson, N.; Backlin, C.; Sundstrom, C.; Nilsson, K.; Enblad, G.; Nilsson, G. Expression of CCL5/RANTES by Hodgkin and Reed-Sternberg cells and its possible role in the recruitment of mast cells into lymphomatous tissue. *Int. J. Cancer* 2003, 107, 197–201. [CrossRef]
111. Kryczek, I.; Lange, A.; Mottram, P.; Alvarez, X.; Cheng, P.; Hogan, M.; Moons, L.; Wei, S.; Zou, L.; Machelon, V.; et al. CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Res. 2005, 65, 465–472.

112. Romagnani, P.; De Paulis, A.; Beltrame, C.; Annunziato, F.; Dente, V.; Maggi, E.; Romagnani, S.; Marone, G. Tryptase-chymase double-positive human mast cells express the eotaxin receptor CCR3 and are attracted by CCR3-binding chemokines. Am. J. Pathol. 1999, 155, 1195–1204. [CrossRef]

113. Zhu, X.Q.; Lv, J.Q.; Lin, Y.; Xiang, M.; Gao, B.H.; Shi, Y.F. Expression of chemokines CCL5 and CCL11 by smooth muscle tumor cells of the uterus and its possible role in the recruitment of mast cells. Gynecol. Oncol. 2007, 105, 650–656. [CrossRef]

114. Polajeva, J.; Sjosten, A.M.; Lager, N.; Kastemar, M.; Waern, I.; Alafuzo, G.; Uhrbom, L.; et al. Mast cell accumulation in glialblomaoma with a potential role for stem cell factor and chemokine CXCL12. PLoS ONE 2011, 6, e25222. [CrossRef]

115. Lin, T.J.; Issekutz, T.B.; Marshall, J.S. SDF-1 induces IL-8 production and transendothelial migration of human cord blood-derived mast cells. Int. Arch. Allergy Immunol. 2001, 124, 142–145. [CrossRef]

116. Juremalm, M.; Hjertson, M.; Olsson, N.; Harvima, I.; Nilsson, K.; Nilsson, G. The chemokine receptor CXCR4 is expressed within the mast cell lineage and its ligand stromal cell-derived factor-1alpha acts as a mast cell chemotaxin. Eur. J. Immunol. 2000, 30, 3614–3622. [CrossRef]

117. Godot, V.; Arock, M.; Garcia, G.; Capel, F.; Flys, C.; Dy, M.; Emilie, D.; Humbert, M. H4 histamine receptor mediates optimal migration of mast cell precursors to CXCL12. J. Allergy Clin. Immunol. 2007, 120, 827–834. [CrossRef]

118. Weller, C.L.; Collington, S.J.; Hartnell, A.; Conroy, D.M.; Kaise, T.; Barker, J.E.; Wilson, M.S.; Taylor, G.W.; Jose, P.J.; Williams, T.J. Chemotactic action of prostaglandin E2 on mouse mast cells acting via the PGE2 receptor 3. Proc. Natl. Acad. Sci. USA 2007, 104, 11712–11717. [CrossRef]

119. Nagasaka, A.; Matsue, H.; Matsushima, H.; Aoki, R.; Nakamura, Y.; Kambe, N.; Kon, S.; Uede, T.; Shimada, S. Osteopontin is produced by mast cells and affects IgE-mediated degranulation and migration of mast cells. Eur. J. Immunol. 2008, 38, 489–499. [CrossRef]

120. Marquardt, D.L.; Gruber, H.E.; Wasserman, S.I. Adenosine release from stimulated mast cells. Proc. Natl. Acad. Sci. USA 1984, 81, 6192–6196. [CrossRef]

121. Gottfried, E.; Kreutz, M.; Mackensen, A. Tumor metabolism as modulator of immune response and tumor progression. Semin. Cancer Biol. 2012, 22, 335–341. [CrossRef]

122. Di Virgilio, F.; Sarti, A.C.; Falzoni, S.; De Marchi, E.; Adinolfi, E. Extracellular ATP and P2 purinergic signalling in the tumour microenvironment. Nat. Rev. Cancer 2018, 18, 601–618. [CrossRef]

123. Granata, F.; Frattini, A.; Loi, J.; Pfizenmaier, K.; Garattini, S.; Frezza, C.; et al. Production of vascular endothelial growth factors from human lung macrophages induced by group IIA and group X secreted phospholipases A2. J. Immunol. 2005, 174, 6192–6196. [CrossRef]

124. Visciano, C.; Prevete, N.; Liotti, F.; Marone, G. Tumor-Associated Mast Cells in Thyroid Cancer. Int. J. Endocrinol. 2015, 2015, 705169. [CrossRef]

125. Gulliksson, M.; Carvalho, R.F.; Ulleras, E.; Nilsson, G. Mast cell survival and mediator secretion in response to hypoxia. PLoS ONE 2010, 5, e12360. [CrossRef]

126. Walczak-Drzewiecka, A.; Ratajewski, M.; Wagner, W.; Dastych, J. HIF-1alpha is up-regulated in activated mast cells by a process that involves calcineurin and NFAT. J. Immunol. 2008, 181, 1665–1672. [CrossRef]

127. Redegeld, F.A.; van der Heijden, M.W.; Kool, M.; Heijdra, B.M.; Garssen, J.; Kraneveld, A.D.; Van Loveren, H.; Roholl, P.; Last, S.; Verbeek, J.S.; et al. Immunoglobulin-free light chains elicit immediate hypersensitivity-like responses. Nat. Med. 2002, 8, 694–701. [CrossRef]

128. Thio, M.; Groot Kormelink, T.; Fischer, M.J.; Blokhuis, B.R.; Nijkamp, F.P.; Redegeld, F.A. Antigen binding characteristics of immunoglobulin free light chains: Crosslinking by antigen is essential to induce allergic inflammation. PLoS ONE 2012, 7, e40986. [CrossRef]

129. Ly, Y.P.; Peng, L.S.; Wang, Q.H.; Chen, N.; Teng, Y.S.; Wang, T.T.; Mao, F.Y.; Zhang, J.Y.; Cheng, P.; Liu, Y.G.; et al. Degranulation of mast cells induced by gastric cancer-derived adrenomedullin prompts gastric cancer progression. Cell Death Dis. 2018, 9, 1034. [CrossRef]

130. Gabrilovich, D.I.; Nagaraj, S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 2009, 9, 162–174. [CrossRef]
131. Yang, Z.; Zhang, B.; Li, D.; Lv, M.; Huang, C.; Shen, G.X.; Huang, B. Mast cells mobilize myeloid-derived suppressor cells and Treg cells in tumor microenvironment via IL-17 pathway in murine hepatocarcinoma model. *PloS ONE* 2010, 5, e8922. [CrossRef]

132. Cheon, E.C.; Khazaie, K.; Khan, M.W.; Strouch, M.J.; Krantz, S.B.; Phillips, J.; Blatner, N.R.; Hix, L.M.; Zhang, M.; Dennis, K.L.; et al. Mast cell 5-lipoxygenase activity promotes intestinal polyposis in APCDelta468 mice. *Cancer Res.* 2011, 71, 1627–1636. [CrossRef]

133. Danelli, L.; Frossi, B.; Gri, G.; Mion, F.; Guarnotta, C.; Bongiovanni, L.; Tripodo, C.; Mariuzzi, L.; Marzinotto, S.; Rigoni, A.; et al. Mast cells boost myeloid-derived suppressor cell activity and contribute to the development of tumor-favoring microenvironment. *Cancer Immunol. Res.* 2015, 3, 85–95. [CrossRef]

134. Saleem, S.J.; Martin, R.K.; Morales, J.K.; Sturgill, J.L.; Gibb, D.R.; Graham, L.; Bear, H.D.; Manjili, M.H.; Ryan, J.J.; Conrad, D.H. Cutting edge: Mast cells critically augment myeloid-derived suppressor cell activity. *J. Immunol.* 2012, 189, 511–515. [CrossRef]

135. Zheng, W.; Aspelund, A.; Alitalo, K. Lymphangiogenic factors, mechanisms and applications. *J. Clin. Investig.* 2014, 124, 878–887. [CrossRef]

136. Lee, S.J.; Park, C.; Lee, J.Y.; Kim, S.; Kwon, P.J.; Kim, W.; Jeon, Y.H.; Lee, E.; Yoon, Y.S. Generation of pure lymphatic endothelial cells from human pluripotent stem cells and their therapeutic effects on wound repair. *Sci Rep.* 2015, 5, 11019. [CrossRef]

137. Kim, H.; Kataru, R.P.; Koh, G.Y. Inflammation-associated lymphangiogenesis: A double-edged sword? *J. Clin. Investig.* 2014, 124, 936–942. [CrossRef]

138. Rivera, L.B.; Bergers, G. Intertwined regulation of angiogenesis and immunity by myeloid cells. *Trends Immunol.* 2015, 36, 240–249. [CrossRef]

139. Dieterich, L.C.; Detmar, M. Tumor lymphangiogenesis and new drug development. *Adv Drug Deliv Rev.* 2016, 99, 148–160. [CrossRef]

140. Randolph, G.J.; Ivanov, S.; Zinselmeyer, B.H.; Scallan, J.P. The Lymphatic System: Integral Roles in Immunity. *Annu. Rev. Immunol.* 2017, 35, 31–52. [CrossRef]

141. Zachary, I. Neuropilins: Role in signalling, angiogenesis and disease. *Chem. Immunol. Allergy* 2014, 99, 37–70.

142. Simons, M.; Gordon, E.; Claesson-Welsh, L. Mechanisms and regulation of endothelial VEGF receptor signalling. *Nat. Rev. Mol. Cell Biol.* 2016, 17, 611–625. [CrossRef]

143. Tammela, T.; Saaristo, A.; Lohepa, M.; Morisada, T.; Tornberg, J.; Norrmén, C.; Oike, Y.; Pajusola, K.; Thurston, G.; Suda, T.; et al. Angiopoietin-1 promotes lymphatic sprouting and hyperplasia. *Blood* 2005, 105, 4642–4648. [CrossRef]

144. Karaman, S.; Leppanen, V.M.; Alitalo, K. Vascular endothelial growth factor signaling in development and disease. *Development* 2018, 145, dev151019. [CrossRef]

145. Heinolainen, K.; Karaman, S.; D’Amico, G.; Tammela, T.; Sormunen, R.; Eklund, L.; Alitalo, K.; Zarkada, G. VEGFR3 Modulates Vascular Permeability by Controlling VEGF/VEGFR2 Signaling. *Circ. Res.* 2017, 120, 1414–1425. [CrossRef]

146. Senger, D.R.; Galli, S.J.; Dvorak, A.M.; Perruzzi, C.A.; Harvey, V.S.; Dvorak, H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. *Science* 1983, 219, 983–985. [CrossRef]

147. Loffredo, S.; Borriello, F.; Iannone, R.; Ferrara, A.L.; Galdiero, M.R.; Gigantino, V.; Esposito, P.; Varricchi, G.; Lambeau, G.; Cassatella, M.A.; et al. Group V Secreted Phospholipase A2 Induces the Release of Proangiogenic and Antiangiogenic Factors by Human Neutrophils. *Front. Immunol.* 2017, 8, 443. [CrossRef]

148. Barleon, B.; Sozzani, S.; Zhou, D.; Weich, H.A.; Mantovani, A.; Marme, D. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. *Blood* 1996, 87, 3336–3343.

149. de Paulis, A.; Prevete, N.; Fiorentino, I.; Rossi, F.W.; Staibano, S.; Montuori, N.; Rago, P.; Longobardi, A.; Liccardo, B.; Genovese, A.; et al. Expression and functions of the vascular endothelial growth factors and their receptors in human basophils. *J. Immunol.* 2006, 177, 7322–7331. [CrossRef]

150. Staiano, R.I.; Loffredo, S.; Borriello, F.; Iannotti, F.A.; Piscitelli, F.; Orlando, P.; Secondo, A.; Granata, F.; Lepore, M.T.; Fiorelli, A.; et al. Human lung-resident macrophages express CB1 and CB2 receptors whose activation inhibits the release of angiogenic and lymphangiogenic factors. *J. Leukoc. Biol.* 2016, 99, 531–540. [CrossRef]

151. Bry, M.; Kivela, R.; Leppanen, V.M.; Alitalo, K. Vascular endothelial growth factor-B in physiology and disease. *Physiol. Rev.* 2014, 94, 779–794. [CrossRef]
152. Clauss, M.; Weich, H.; Breier, G.; Knies, U.; Rockl, W.; Waltenberger, J.; Risau, W. The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. *J. Biol. Chem.* 1996, 271, 17629–17634. [CrossRef]

153. Eklund, L.; Kangas, J.; Saharinen, P. Angiopoietin-Tie signalling in the cardiovascular and lymphatic systems. *Clin. Sci.* 2017, 131, 87–103. [CrossRef]

154. Eklund, L.; Saharinen, P. Angiopoietin signaling in the vasculature. *Exp. Cell Res.* 2013, 319, 1271–1280. [CrossRef]

155. Bosisio, D.; Ronca, R.; Salvi, V.; Presta, M.; Sozzani, S. Dendritic cells in inflammatory angiogenesis and lymphangiogenesis. *Curr. Opin. Immunol.* 2018, 53, 180–186. [CrossRef]

156. Meng, X.; Yu, X.; Dong, Q.; Xu, X.; Li, J.; Xu, Q.; Ma, J.; Zhou, C. Distribution of circulating follicular helper T cells. *Clin. Sci.* 2017, 131, 87–103. [CrossRef]

157. Boesiger, J.; Tsai, M.; Maurer, M.; Yamaguchi, M.; Brown, L.F.; Claffey, K.P.; Dvorak, H.F.; Galli, S.J. Mast cells can secrete vascular permeability factor/vascular endothelial cell growth factor and exhibit enhanced release after immunoglobulin E-dependent upregulation of fcepsilon receptor I expression. *J. Exp. Med.* 1998, 188, 1135–1145. [CrossRef]

158. Abdel-Majid, R.M.; Marshall, J.S. Prostaglandin E2 induces degranulation-independent production of vascular endothelial growth factor by human mast cells. *J. Immunol.* 2004, 172, 1227–1236. [CrossRef]

159. Varricchi, G.; Granata, F.; Loffredo, S.; Genovese, A.; Marone, G. Angiogenesis and lymphangiogenesis in inflammatory skin disorders. *J. Am. Acad. Dermatol.* 2015, 73, 144–153. [CrossRef]

160. Theoharides, T.C.; Zhang, B.; Kempuraj, D.; Tagen, M.; Vasiadi, M.; Angelidou, A.; Alysandratos, K.D.; Kalogeromitros, D.; Asadi, S.; Slavrianeas, N.; et al. IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin. *Proc. Natl. Acad. Sci. USA* 2010, 107, 4448–4453. [CrossRef]

161. Wroblewski, M.; Bauer, R.; Cubas Cordova, M.; Udonta, F.; Ben-Batalla, I.; Legler, K.; Egberts, J.; Janning, M.; Velthaus, J.; et al. Mast cells decrease efficacy of anti-angiogenic therapy by secreting matrix-degrading granzyme B. *Nat. Commun.* 2017, 8, 269. [CrossRef]

162. Varricchi, G.; Galdiero, M.R.; Loffredo, S.; Lucarini, V.; Marone, G.; Mattei, F.; Schiavoni, G. Eosinophils: The unsung heroes in cancer? *Oncoimmunology* 2018, 7, e1393134. [CrossRef]

163. Carretero, R.; Sektioglu, I.M.; Garbi, N.; Salgado, O.C.; Beckhove, P.; Hammerling, G.J. Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells. *Nat. Immunol.* 2015, 16, 609–617. [CrossRef]

164. Lucarini, V.; Ziccheddu, G.; Macchia, I.; La Sorsa, V.; Peschiarioli, F.; Buccione, C.; Sistiagu, A.; Sanchez, M.; Andreone, S.; D’Urso, M.T.; et al. IL-33 restricts tumor growth and inhibits pulmonary metastasis in melanoma-bearing mice through eosinophils. *Oncoimmunology* 2017, 6, e1317420. [CrossRef]

165. Meng, X.; Yu, X.; Dong, Q.; Xu, X.; Li, J.; Xu, Q.; Ma, J.; Zhou, C. Distribution of circulating follicular helper T cells and expression of interleukin-21 and chemokine C-X-C ligand 13 in gastric cancer. *Oncol. Lett.* 2018, 16, 3917–3922. [CrossRef]

166. Afferni, C.; Buccione, C.; Andreone, S.; Galdiero, M.R.; Varricchi, G.; Marone, G.; Mattei, F.; Schiavoni, G. The Pleiotropic Immunomodulatory Functions of IL-33 and Its Implications in Tumor Immunity. *Front. Immunol.* 2018, 9, 2601. [CrossRef] [PubMed]

167. Galdiero, M.R.; Varricchi, G.; Seaf, M.; Marone, G.; Levi-Schaffer, F. Bidirectional Mast Cell-Eosinophil Interactions in Inflammatory Disorders and Cancer. *Front. Med.* 2017, 4, 103. [CrossRef] [PubMed]

168. Ammendola, M.; Sacco, R.; Donato, G.; Zuccala, V.; Russo, E.; Luposella, M.; Vescio, G.; Rizzuto, A.; Patruno, R.; De Sarro, G.; et al. Mast cell positivity to tryptase correlates with metastatic lymph nodes in gastrointestinal cancer patients treated surgically. *Oncoimmunology* 2013, 85, 111–116. [CrossRef]

169. Ammendola, M.; Sacco, R.; Sammarco, G.; Donato, G.; Zuccala, V.; Romano, R.; Luposella, M.; Patruno, R.; Vallicelli, C.; Verdecchia, G.M.; et al. Mast Cells Positive to Tryptase and c-Kit Receptor Expressing Cells Correlates with Angiogenesis in Gastric Cancer Patients Surgically Treated. *Gastroenterol. Res. Pract.* 2013, 2013, 703163. [CrossRef] [PubMed]

170. Li, Y.; Zhao, Y.; Wang, X.; Chen, N.; Mao, F.; Teng, Y.; Wang, T.; Peng, L.; Zhang, J.; Cheng, P.; et al. Increased intratumoral mast cells foster immune suppression and gastric cancer progression through TNF-alpha-PD-L1 pathway. *J. Immunother. Cancer* 2019, 7, 54. [CrossRef] [PubMed]
171. Wang, J.T.; Li, H.; Zhang, H.; Chen, Y.F.; Cao, Y.F.; Li, R.C.; Lin, C.; Wei, Y.C.; Xiang, X.N.; Fang, H.J.; et al. Intratumoral IL17-producing cells infiltration correlate with antitumor immune contexte and improved response to adjuvant chemotherapy in gastric cancer. Ann. Oncol. 2019, 30, 266–273. [CrossRef] [PubMed]

172. Chang, D.Z.; Ma, Y.; Ji, B.; Wang, H.; Deng, D.; Liu, Y.; Abbruzzese, J.L.; Liu, Y.J.; Logsdon, C.D.; Hwu, P. Mast cells in tumor microenvironment promotes the in vivo growth of pancreatic ductal adenocarcinoma. Clin. Cancer Res. 2011, 17, 7015–7023. [CrossRef] [PubMed]

173. Ammendola, M.; Sacco, R.; Sammarco, G.; Donato, G.; Montemurro, S.; Ruggieri, E.; Patruno, R.; Marech, I.; et al. Mast cells contribute to the generation of an angiogenic phenotype in pancreatic ductal adenocarcinoma. J. Clin. Pathol. 2004, 57, 630–636. [CrossRef]

174. Soucek, L.; Buggy, J.J.; Kortlever, R.; Adimoolam, S.; Monclus, H.A.; Allende, M.T.; Swigart, L.B.; Evan, G.I. Mast Cells Comprise the Major of Interleukin -Producing Cells and Predict a Poor Prognosis in Hepatocellular Carcinoma. Medicine 2016, 3, 1093–1100. [CrossRef]

175. Soucek, L.; Lawlor, E.R.; Soto, D.; Shchors, K.; Swigart, L.B.; Evan, G.I. Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat. Med. 2007, 13, 1211–1218. [CrossRef]

176. Strouch, M.J.; Cheon, E.C.; Salabat, M.R.; Krantz, S.B.; Gounaris, E.; Melstrom, L.G.; Dangi-Garimella, S.; Wang, E.; Munshi, H.G.; Khazaie, K.; et al. Crossstalk between mast cells and pancreatic cancer cells contributes to pancreatic tumor progression. Clin. Cancer Res. 2010, 16, 2257–2265. [CrossRef]

177. Rao, Q.; Chen, Y.; Yeh, C.R.; Ding, J.; Li, L.; Chang, C.; Yeh, S. Recruited mast cells in the tumor microenvironment enhance bladder cancer metastasis via modulation of ERbeta/CCL2/CCR2 EMT/MMP9 signals. Oncotarget 2016, 7, 7842–7855. [CrossRef]

178. Suzuki, S.; Ichikawa, Y.; Nakagawa, K.; Kumamoto, T.; Mori, R.; Matsuyama, R.; Takeda, K.; Ota, M.; Tanaka, K.; Tamura, T.; et al. High infiltration of mast cells positive to tryptase predicts worse outcome following resection of colorectal liver metastases. BMC Cancer 2015, 15, 840. [CrossRef]

179. Ammendola, M.; Sacco, R.; Sammarco, G.; Donato, G.; Montemurro, S.; Ruggieri, E.; Patruno, R.; Marech, I.; Cariello, M.; Vacca, A.; et al. Correlation between serum tryptase, mast cells positive to tryptase and microvascular density in colo-rectal cancer patients: Possible biological-clinical significance. PLoS ONE 2014, 9, e99512. [CrossRef]

180. Malfetone, A.; Silvestris, N.; Saponaro, C.; Ranieri, G.; Russo, A.; Caruso, S.; Popescu, O.; Simone, G.; Paradiso, A.; Mangia, A. High density of tryptase-positive mast cells in human colorectal cancer: A poor prognostic factor related to protease-activated receptor 2 expression. J. Cell. Mol. Med. 2013, 17, 1025–1037. [CrossRef]

181. Gulubova, M.; Vlaykova, T. Prognostic significance of mast cell number and microvascular density for the survival of patients with primary colorectal cancer. J. Gastroenterol. Hepatol. 2009, 24, 1265–1275. [CrossRef]

182. Tu, J.F.; Fan, H.Y.; Ying, X.H.; Lou, J.; Ji, J.S.; Kou, H. Mast Cells Comprise the Major of Interleukin 17-Producing Cells and Predict a Poor Prognosis in Hepatocellular Carcinoma. Medicine 2016, 95, e3220. [CrossRef]

183. Ammendola, M.; Sacco, R.; Sammarco, G.; Piardi, T.; Zuccala, V.; Patruno, R.; Zullo, A.; Zizzo, N.; Nardo, B.; Marech, I.; et al. Mast cells positive to tryptase, endothelial cells positive to protease-activated receptor-2 and microvascular density correlate among themselves in hepatocellular carcinoma patients who have undergone surgery. Oncol. Targets Ther. 2016, 9, 4465–4471.

184. Ju, M.J.; Qiu, S.J.; Gao, Q.; Fan, J.; Cai, M.Y.; Li, Y.W.; Tang, Z.Y. Combination of peritumoral mast cells and T-regulatory cells predicts prognosis of hepatocellular carcinoma. Cancer Sci. 2009, 100, 1267–1274. [CrossRef]

185. Nakayama, T.; Yao, L.; Tosato, G. Mast cell-derived angiopoietin-1 plays a critical role in the growth of plasma cell tumors. J. Clin. Investig. 2004, 114, 1317–1325. [CrossRef]

186. Amini, R.M.; Aaltonen, K.; Nevanlinna, H.; Carvalho, R.; Salonen, L.; Heikkila, P.; Blomqvist, C. Mast cells and eosiinophils in invasive breast carcinoma. BMC Cancer 2007, 7, 165. [CrossRef]

187. Dabiri, S.; Huntsman, D.; Makretsov, N.; Cheang, M.; Voduc, D.K.; Leung, S.; Gelmon, K.A.; Gilks, C.B.; Huntsman, D.G. Mast cells in invasive breast cancer are a marker of favourable prognosis: A study of 4,444 cases. Breast Cancer Res. Treat. 2008, 107, 249–257. [CrossRef]
189. Zhao, S.G.; Lehrer, J.; Chang, S.L.; Das, R.; Erho, N.; Liu, Y.; Sjostrom, M.; Den, R.B.; Freedland, S.J.; Klein, E.A.; et al. The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target. *J. Natl. Cancer Inst.* **2019**, *111*, 301–310. [CrossRef]

190. Carlini, M.J.; Dalurzo, M.C.; Lastiri, J.M.; Smith, D.E.; Vasallo, B.C.; Puricelli, L.I.; Lauria de Cidre, L.S. Mast cell phenotypes and microvessels in non-small cell lung cancer and its prognostic significance. *Hum. Pathol.* **2010**, *41*, 697–705. [CrossRef]

191. Bruni, C.; Caschera, F. Quantitative assessment of mast cell infiltration around gastric cancer cells correlates with tumor angiogenesis and metastasis. *Gastric Cancer* **2019**, *26*, 26–32. [CrossRef]

192. Pittoni, P.; Colombo, M.P. The dark side of mast cell-targeted therapy in prostate cancer. *Cancer Res.* **2012**, *72*, 831–835. [CrossRef]

193. Shikotra, A.; Ohri, C.M.; Green, R.H.; Waller, D.A.; Bradding, P. Mast cell phenotype, TNFalpha expression and degranulation status in non-small cell lung cancer. *Sci. Rep.* **2016**, *6*, 38352. [CrossRef]

194. Welsh, T.J.; Green, R.H.; Richardson, D.; Waller, D.A.; O’Byrne, K.J.; Bradding, P. Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. *J. Clin. Oncol.* **2005**, *23*, 8959–8967. [CrossRef]

195. Cai, S.W.; Yang, S.Z.; Gao, J.; Pan, K.; Chen, J.Y.; Wang, Y.L.; Wei, L.X.; Dong, J.H. Prognostic significance of mast cell count following curative resection for pancreatic ductal adenocarcinoma. *Surgery* **2011**, *149*, 576–584. [CrossRef]

196. Holzel, M.; Landsberg, J.; Glodde, N.; Bald, T.; Rogava, M.; Riesenberg, S.; Becker, A.; Jonsson, G.; Tuting, T. A Preclinical Model of Malignant Peripheral Nerve Sheath Tumor-like Melanoma Is Characterized by Infiltrating Mast Cells. *Cancer Res.* **2016**, *76*, 251–263. [CrossRef]

197. Zuccala, V.; Luposella, M.; Patruno, R.; Zizzo, N.; Gadaleta, C.; Marech, I.; Ruggieri, R.; et al. Tryptase mast cell density, protease-activated receptor-2 microvascular density and classical microvascular density evaluation in gastric cancer patients undergoing surgery: Possible translational relevance. *Ther. Adv. Gastroenterol.* **2017**, *10*, 353–360. [CrossRef]
221. Varricchi, G.; Pecoraro, A.; Lo Hueber, A.J.; Asquith, D.L.; Miller, A.M.; Reilly, J.; Kerr, S.; Leipe, J.; Melendez, A.J.; McInnes, I.B. Mast cells

214. Leporini, C.; Ammendola, M.; Marech, I.; Sammarco, G.; Sacco, R.; Gadaleta, C.D.; Oakley, C.; Russo, E.; De Sarro, G.; Ranieri, G. Targeting mast cells in gastric cancer with special reference to bone metastases. World J. Gastroenterol. 2015, 21, 10493–10501. [CrossRef]

211. Yamada, Y.; Saito, H.; Ikeguchi, M. Prevalence and clinical relevance of Th17 cells in patients with gastric cancer. J. Surg. Res. 2012, 178, 685–691. [CrossRef]

210. Liu, X.; Jin, H.; Zhang, G.; Lin, X.; Chen, C.; Sun, J.; Zhang, Y.; Zhang, Q.; Yu, J. Intratumor IL-17-positive mast cells are the major source of the IL-17 that is predictive of survival in gastric cancer patients. PLoS ONE 2014, 9, e106834. [CrossRef] [PubMed]

209. Ammendola, M.; Sacco, R.; Sammarco, G.; Luposella, M.; Patruno, R.; Gadaleta, C.D.; Sarro, G.D.; Ranieri, G. Mast Cell-Targeted Strategies in Cancer Therapy. Transfus. Med. Hemother. 2016, 43, 109–113. [CrossRef]
228. Tocchetti, C.G.; Galdiero, M.R.; Varricchi, G. Cardiac Toxicity in Patients Treated With Immune Checkpoint Inhibitors: It Is Now Time for Cardio-Immuno-Oncology. *J. Am. Coll. Cardiol.* 2018, 71, 1765–1767. [CrossRef]

229. Seo, A.N.; Kang, B.W.; Kwon, O.K.; Park, K.B.; Lee, S.S.; Chung, H.Y.; Yu, W.; Bae, H.I.; Jeon, S.W.; Kang, H.; et al. Intratumoral PD-L1 expression is associated with worse survival of patients with Epstein-Barr virus-associated gastric cancer. *Br. J. Cancer* 2017, 117, 1753–1760. [CrossRef]

230. De Rosa, S.; Sahnane, N.; Tibiletti, M.G.; Magnoli, F.; Vanoli, A.; Sessa, F.; Chiaravalli, A.M. EBV(+) and MSI Gastric Cancers Harbor High PD-L1/PD-1 Expression and High CD8(+) Intratumoral Lymphocytes. *Cancers* 2018, 10, 102. [CrossRef]

231. Ammendola, M.; Leporini, C.; Marech, I.; Gadaleta, C.D.; Scognamillo, G.; Sacco, R.; Sammarco, G.; De Sarro, G.; Russo, E.; Ranieri, G. Targeting mast cells tryptase in tumor microenvironment: A potential antiangiogenetic strategy. *Biomed. Res. Int.* 2014, 2014, 154702. [CrossRef]

232. Yu, J.; Zhang, Y.; Leung, L.H.; Liu, L.; Yang, F.; Yao, X. Efficacy and safety of angiogenesis inhibitors in advanced gastric cancer: A systematic review and meta-analysis. *J. Hematol. Oncol.* 2016, 9, 111. [CrossRef]

233. Chan, D.L.; Sjoquist, K.M.; Goldstein, D.; Price, T.J.; Martin, A.J.; Bang, Y.J.; Kang, Y.K.; Pavlakis, N. The effect of anti-angiogenic agents on overall survival in metastatic oesophago-gastric cancer: A systematic review and meta-analysis. *PLoS ONE* 2017, 12, e0172307. [CrossRef] [PubMed]

234. Lotfi-Emran, S.; Ward, B.R.; Le, Q.T.; Pozez, A.L.; Manjili, M.H.; Woodfolk, J.A.; Schwartz, L.B. Human mast cells present antigen to autologous CD4(+) T cells. *J. Allergy Clin. Immunol.* 2018, 141, 311–321. [CrossRef]

235. Kritikou, E.; van der Heijden, T.; Swart, M.; van Duijn, J.; Slutter, B.; Wezel, A.; Smeets, H.J.; Maffia, P.; Kuiper, J.; Bot, I. Hypercholesterolemia Induces a Mast Cell-CD4(+) T Cell Interaction in Atherosclerosis. *J. Immunol.* 2019, 202, 1531–1539. [CrossRef] [PubMed]

236. Zaidi, N.; Jaffe, E.M. Immunotherapy transforms cancer treatment. *J. Clin. Investig.* 2019, 129, 46–47. [CrossRef]

237. Wu, C.; Zhu, Y.; Jiang, J.; Zhao, J.; Zhang, X.G.; Xu, N. Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. *Acta Histochem.* 2006, 108, 19–24. [CrossRef] [PubMed]

238. Derks, S.; Liao, X.; Chiaravalli, A.M.; Xu, X.; Camargo, M.C.; Scolia, E.; Sessa, F.; Fleitas, T.; Freeman, G.J.; Rodig, S.J.; et al. Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers. *Oncotarget* 2016, 7, 32925–32932. [CrossRef] [PubMed]

239. Galli, S.J.; Borregaard, N.; Wynn, T.A. Phenotypic and functional plasticity of cells of innate immunity: Macrophages, mast cells and neutrophils. *Nat. Immunol.* 2011, 12, 1035–1044. [CrossRef] [PubMed]

240. Schiavoni, G.; Gabriele, L.; Mattei, F. The tumor microenvironment: A pitch for multiple players. *Front. Oncol.* 2013, 3, 90. [CrossRef] [PubMed]

241. Valkenburg, K.C.; de Groot, A.E.; Pienta, K.J. Targeting the tumour stroma to improve cancer therapy. *Nat. Rev. Clin. Oncol.* 2018, 15, 366–381. [CrossRef]